The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.
Patient has measurable disease by RECIST v1.1
Recurrent or metastatic triple-negative breast cancer patients as per current ASCO/CAP guidelines
Patient has received prior treatment with a taxane and an antibody-drug conjugate with a topoisomerase inhibitor payload.
Patient has received no more than 3 prior lines of cytotoxic therapy in the locally advanced or metastatic setting.
Have received any prior treatment with enfortumab vedotin, tisotumab vedotin or other MMAE based or nectin-4 targeted antibody-drug conjugates.
Unstable CNS metastasis requiring treatment in the last 28 days.
Acute infection requiring IV treatment in the last 14 days.
Grade ≥2 peripheral neuropathy.